Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation

Abstract

Background Liver transplant population has been considered as a special population in the treatment of hepatitis C virus infection, not only because of lower sustained virological response (SVR) rates in comparison with pretransplant setting, but also for other aspects (i.e., immunosuppressive therapy, renal function, drug–drug interactions). We aimed to evaluate the efficacy and safety of the combined treatment with sofosbuvir and daclatasvir with or without ribavirin in liver transplant recipients with recurrent hepatitis C following transplantation and screening for the development of hepatocellular carcinoma during treatment, after the end of treatment, or during follow-up. This multicenteric prospective study was conducted in Egypt. This study included 40 patients who underwent living donor liver transplantation that started treatment at least 3 months following transplantation. All participants received 400 mg sofosbuvir once daily plus daclatasvir 60 mg daily ± ribavirin. Treatment lasted for up to 24 weeks, and participants were followed up as outpatients monthly for 12 and 24 weeks and 36 weeks post-treatment to determine sustained virological response (SVR12 and SVR24), considered to be a cure and detection of any changes in tumor markers or radiological imaging during follow-up. Results In the current study, 40 patients (100%) have good response to treatment during treatment and during follow-up (SVR 12 was 100%). No abnormal side effects to treatment were detected; also, no drug–drug interactions were noted during the treatment. Conclusions Treatment of HCV after living donor liver transplantation with combined sofosbuvir and daclatasvir is safe and well-tolerated and provides high rates of SVR.

Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C

“…A total of 150 confirmed cases of HCV infection were included in this investigation, with the majority of the cases (58.67 percent) being male. These findings are consistent with some other studies conducted to examine the effects of Antiviral Therapy in Hepatitis C infected patients, in which the male patient population rate was higher than the female patient population rate by 25 to 43 percent [13][14], indicating a similarity between the two studies.…”

Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents

“…Patients received DAA therapy in the form of “sofosbuvir (400 mg) and daclatasvir (60 mg) ± ribavirin (1000–1200 mg according to the body weight” for 12 weeks based on the protocol provided by the National Committee for Control of Viral Hepatitis in Egypt (NCCVH guidelines for the management of adult patients with HCV infection) available at the time of enrolment [ 47 ]. The combination of sofosbuvir and daclatasvir remains an acceptable option, according to the EASL Recommendations for Treatment of Hepatitis C 2016 [ 49 , 50 , 51 , 52 , 53 ]. SVR was defined as non-detectable HCV-RNA in serum after six months of treatment.…”